Share on StockTwits
 

BioMarin Pharmaceutical (NASDAQ:BMRN) was upgraded by equities researchers at McLean Capital Management from a “sell” rating to a “neutral” rating in a research report issued on Friday, Stock Ratings News reports.

A number of other firms have also recently commented on BMRN. Analysts at Barclays raised their price target on shares of BioMarin Pharmaceutical from $73.00 to $76.00 in a research note on Wednesday. They now have an “equal weight” rating on the stock. Separately, analysts at Jefferies Group reiterated a “buy” rating on shares of BioMarin Pharmaceutical in a research note on Wednesday. They now have a $87.00 price target on the stock. They noted that the move was a valuation call. Finally, analysts at Citigroup Inc. raised their price target on shares of BioMarin Pharmaceutical from $79.00 to $90.00 in a research note on Wednesday. Ten analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $79.31.

Shares of BioMarin Pharmaceutical (NASDAQ:BMRN) traded up 1.73% during mid-day trading on Friday, hitting $81.52. 2,192,598 shares of the company’s stock traded hands. BioMarin Pharmaceutical has a 1-year low of $53.35 and a 1-year high of $80.67. The stock has a 50-day moving average of $70.85 and a 200-day moving average of $68.91. The company’s market cap is $11.593 billion.

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) develops and commercializes pharmaceuticals for serious diseases and medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.